Citat:
Ursprungligen postat av
Varglig
Och därefter tillbakadragen.
Så slutsatsen är naturligtvis inte alls "vi visste" utan att den hamnade i papperskorgen av okänd anledning.
killen som skrev undersökningen. Tror du helt seriöst att den killen gör några nybörjar misstag.
Mandeep R. Mehra (born December 1967 in Delhi) is The William Harvey Distinguished Chair in Advanced Cardiovascular Medicine and a
professor of medicine at Harvard Medical School. He is the medical director of the Brigham Heart and Vascular Center in Boston, Massachusetts, and specializes in advanced heart failure, mechanical circulatory support and cardiac transplantation.
Usefulness of Ivermectin in COVID-19 Illness
Amit N. Patel MD, MS1,2; Sapan S. Desai MD PhD MBA3
David W. Grainger PhD1, Mandeep R. Mehra,MD, MSc4
1Department of Bioengineering, University of Utah, Salt Lake City, UT;
2HCA Research Institute, Florida;
3Surgisphere Corporation, Chicago, Illinois;
4Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston, MA;
Design: An international, multicenter, observational propensity-score matched case-controlled
study using prospectively collected data on patients diagnosed with COVID-19 between January
1, 2020 and March 31, 2020.
Participants: Hospitalized patients diagnosed with COVID-19 determined by presence of a
positive laboratory finding confirming SARS-CoV-2 infection.
Exposure: Ivermectin (150mcg/Kg) administered once compared with COVID-19 patients
receiving medical therapy without ivermectin.
"Findings: This observational propensity-matched case-controlled study in 1,408 patients (704
that received ivermectin and 704 that did not) demonstrated an association of ivermectin use
with lower in-hospital mortality 1.4% versus 8.5% (Ivermectin versus no ivermectin; HR 0.20 CI
95% 0.11-0.37, p<0.0001)."
https://www.isglobal.org/documents/10179/6022921/Patel+et+al.+2020+version+2.pdf/adf390e0-7099-4c70-91d0-e0f7a0b69e14
